Regulation of Mineralocorticoid Receptor Action
盐皮质激素受体作用的调节
基本信息
- 批准号:10553631
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-01 至 2024-09-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAffinityAlcohol OxidoreductasesAldosteroneAmino AcidsAngiotensin IIAntibodiesAreaBindingBlood PressureBrainCXCR3 geneCardiovascular systemCell LineCellsComplications of Diabetes MellitusCongestive Heart FailureCorticosteroneCortisoneCultured CellsDahl Hypertensive RatsDataDevelopmentDietDistalDominant-Negative MutationEnzymesEpitheliumEssential HypertensionGene ExpressionGenomicsGlucocorticoid ReceptorHeartHistocytochemistryHormonesHumanHydrocortisoneHydroxysteroid DehydrogenasesHyperaldosteronismHypertensionImmunofluorescence ImmunologicIntercalated CellKidneyLigand Binding DomainLigandsLuciferasesMeasuresMediatingMineralocorticoid ReceptorMouse Mammary Tumor VirusMovementNephronsNormal RangeOrganPathogenicityPathologicPatientsPhosphorylationPhosphotransferasesPlasmaPositioning AttributePost-Translational Protein ProcessingPotassiumProtein Tyrosine KinaseRattusReceptor ActivationRegulationReporter GenesReportingRoleSerineSerine/Threonine PhosphorylationSiteSleep Apnea SyndromesSodiumSodium ChlorideSpecificitySteroidsSystemTBK1 geneThreonineTissuesTransactivationWatercell typeinorganic phosphatekidney cellnon-genomicnormotensiveoverexpressionreceptorreceptor bindingresponseserine receptorside effectsteroid hormonetranscription factor
项目摘要
The mineralocorticoid receptor (MR) is a transcription factor expressed in many cells that regulates the
expression of genes in involved myriad cell type-specific functions. Inappropriate activation of the MR causes
hypertension and pathological tissue remodeling even in conditions of normal aldosterone levels. Activity of the
MR is regulated by post-translational modifications including phosphorylation of serines and threonines.
Phosphorylation activates or suppresses MR activity depending upon the amino acid involved. The kinase
ULK1 was recently reported to phosphorylate serine 843 of the MR, thereby suppressing its activity, and to be
expressed with the MR only in intercalated cells of the distal nephron. Our own specific antibodies reveal more
extensive co-expression of ULK1 and MR in the kidney. ULK1 expression is widespread in the body and in
multiple cell lines. Other kinases also have the potential to phosphorylate the MR at S843, thus inhibit MR
activity.
The MR has similar affinity for aldo, cortisol or corticosterone. Specificity for aldo is conferred by conversion of
cortisol and corticosterone to the inactive cortisone and 11-dehydrocorticosterone by the 11β-hydroxysteroid
dehydrogenase 2 (11-HSD2), however this enzyme is not present in most non-epithelial aldo target tissues.
Cortisol and corticosterone are also converted to 20β-dihydro-cortisol and -corticosterone by carbonyl
reductase 1 (Cbr1). We that found the 20β-dihydro metabolites do not activate the MR, thus providing an
alternative mechanism for MR specificity for aldo where 11-HSD2 is not expressed.
Hypotheses: 1) Phosphorylation of the MR at serine 843 is an important negative regulator of MR action that
occurs in multiple tissues. 2) Reduction of the 20-keto of corticosterone and cortisol by carbonyl reductase 1
regulates ligand selectivity for the MR by converting corticosterone and cortisol into the inactive metabolites
20β-dihydrocorticosterone (20β-DHC) and 20β-dihydrocortisol. Both potentially modulate MR activity.
Specific Aim 1: Study the role of phosphorylation of the MR at serine 843 (human) on genomic and non-
genomic activity of the MR. Study the effects of over-expression and suppression of several kinases, ULK1,
ULK2, TBK1, NEK2 and PAK1, with putative ability to phosphorylate the MR at S843 in cells expressing an MR
reporter gene system. Study the distribution and co-localization of the MR with ULK1, ULK2 and other kinases
that catalyze S843 phosphorylation in the kidney, heart, vessels and brain.
Specific Aim 2: Study the role of the 20-keto reduction of cortisol and corticosterone on MR ligand selectivity.
Determine the dynamics of the 20-keto reduction of corticosterone and cortisol by the human and rat Cbr1 in
cells. Measure the conversion of corticosterone to 20β-dihydrocorticosterone in various tissues including in
micropunches from specific areas of the rat brain where we demonstrate that Cbr1 and MR are co-expressed
by immunofluorescent histochemistry. Measure plasma levels of corticosterone and 20β-DHC in plasma and
tissues of rats fed different amounts of salt.
The mechanisms for the cell-specific modulation of MR activity will never be known if not explored and are
crucial for the development of rational therapy with minimal side effects for inappropriate MR activation.
盐皮质激素受体 (MR) 是一种在许多细胞中表达的转录因子,可调节
涉及多种细胞类型特异性功能的基因表达。 MR 激活不当的原因
即使在醛固酮水平正常的情况下,也会出现高血压和病理性组织重塑。的活动
MR 受到翻译后修饰的调节,包括丝氨酸和苏氨酸的磷酸化。
磷酸化激活或抑制 MR 活性取决于所涉及的氨基酸。激酶
最近报道 ULK1 磷酸化 MR 的丝氨酸 843,从而抑制其活性,并且
MR 仅在远端肾单位的闰细胞中表达。我们自己的特异性抗体揭示了更多
ULK1 和 MR 在肾脏中广泛共表达。 ULK1 表达广泛存在于体内
多个细胞系。其他激酶也有可能磷酸化 MR S843,从而抑制 MR
活动。
MR 对醛、皮质醇或皮质酮具有相似的亲和力。 ALDO 的特异性是通过转化而赋予的
皮质醇和皮质酮通过 11β-羟基类固醇转化为无活性的可的松和 11-脱氢皮质酮
脱氢酶 2 (11-HSD2),但大多数非上皮醛靶组织中不存在该酶。
皮质醇和皮质酮也通过羰基转化为20β-二氢皮质醇和20β-二氢皮质酮
还原酶 1 (Cbr1)。我们发现 20β-二氢代谢物不会激活 MR,从而提供了
不表达 11-HSD2 的 ALDO MR 特异性的替代机制。
假设:1) MR 丝氨酸 843 处的磷酸化是 MR 作用的重要负调节因子
发生在多个组织中。 2) 羰基还原酶 1 还原皮质酮和皮质醇的 20-酮基
通过将皮质酮和皮质醇转化为无活性代谢物来调节 MR 的配体选择性
20β-二氢皮质酮(20β-DHC)和20β-二氢皮质醇。两者都可能调节 MR 活动。
具体目标 1:研究 MR 丝氨酸 843(人)磷酸化对基因组和非基因组的作用
MR 的基因组活性。研究几种激酶 ULK1 的过度表达和抑制的影响,
ULK2、TBK1、NEK2 和 PAK1,假定能够在表达 MR 的细胞中磷酸化 S843 处的 MR
报告基因系统。研究 MR 与 ULK1、ULK2 和其他激酶的分布和共定位
催化肾脏、心脏、血管和大脑中的 S843 磷酸化。
具体目标 2:研究皮质醇和皮质酮的 20-酮还原对 MR 配体选择性的作用。
确定人和大鼠 Cbr1 对皮质酮和皮质醇 20-酮还原的动态
细胞。测量各种组织中皮质酮向 20β-二氢皮质酮的转化,包括
来自大鼠大脑特定区域的微穿孔,我们证明 Cbr1 和 MR 是共表达的
通过免疫荧光组织化学。测量血浆和血浆中皮质酮和 20β-DHC 的血浆水平
给老鼠的组织喂食不同量的盐。
如果不进行探索和研究,细胞特异性调节 MR 活性的机制将永远无法得知。
对于开发合理的治疗方法至关重要,并且对于不适当的 MR 激活具有最小的副作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Celso Enrique Gomez-Sanchez其他文献
Celso Enrique Gomez-Sanchez的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Celso Enrique Gomez-Sanchez', 18)}}的其他基金
Adrenal cell ATP1A1 mutations and mechanisms of aldosterone biosynthesis
肾上腺细胞ATP1A1突变与醛固酮生物合成机制
- 批准号:
9981536 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Adrenal cell ATP1A1 mutations and mechanisms of aldosterone biosynthesis
肾上腺细胞ATP1A1突变与醛固酮生物合成机制
- 批准号:
10447775 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Adrenal cell ATP1A1 mutations and mechanisms of aldosterone biosynthesis
肾上腺细胞ATP1A1突变与醛固酮生物合成机制
- 批准号:
9813129 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Adrenal cell ATP1A1 mutations and mechanisms of aldosterone biosynthesis
肾上腺细胞ATP1A1突变与醛固酮生物合成机制
- 批准号:
10210433 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Regulation of the late-pathway of aldosterone biosynthesis
醛固酮生物合成后期途径的调节
- 批准号:
8254384 - 财政年份:2011
- 资助金额:
-- - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
-- - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Continuing Grant














{{item.name}}会员




